Aiming to optimize therapeutic strategies for NASH, a 2023 study by Ren et al. focused on the development of a dual‐target modulator able to activate FXR and to inhibit FABP1. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.